Table 1.
Eleven recruiting practices’ population, prevalence of stage 3–5 CKD, numbers of patients invited, screened and randomised for STOP-CKD study
| Practice | Practice population | Prevalence of stage 3–5 CKD* (%) | Patients eligible from computerised search (%) | Patients excluded by GP (%)† | Patients invited (%) | Patients replying (%)‡ | Patients expressing interest (%)§ | Patients attending screening visit (%)§ | Patients randomised (%)§ |
|---|---|---|---|---|---|---|---|---|---|
| #1¶ | 7501 | 4.72 | 260 (3.5) | 49 (18.8) | 211 (2.8) | 105 (49.8) | 37 (17.5) | 22 (10.4) | 3 (1.4) |
| #2¶ | 3838 | 1.86 | 38 (1.0) | 20(52.6) | 18 (0.5) | 7 (38.9) | 3 (16.7) | 3 (16.7) | 0 |
| #3 | 27 025 | 4.82 | 360 (1.3) | 183 (50.8) | 177 (0.6) | 102 (57.6) | 21 (11.9) | 15 (8.5) | 1 (0.6) |
| #4 | 7113 | 3.58 | 179 (2.5) | 7 (3.9) | 172 (2.4) | 81 (47.1) | 20 (11.6) | 12 (7.0) | 2 (1.2) |
| #5 | 24 553 | 2.97 | 478 (1.9) | 97 (20.3) | 381 (1.6) | 152 (39.9) | 41 (10.8) | 29 (7.6) | 5 (1.3) |
| #6 ¶ | 8729 | 4.19 | 157 (1.8) | 17 (10.8) | 140 (1.6) | 61 (43.6) | 20 (14.3) | 16 (11.4) | 3 (2.1) |
| #7 ¶ | 5817 | 4.69 | 129 (2.2) | 13 (10.1) | 116 (2.0) | 44 (37.9) | 15 (12.9) | 10 (8.6) | 1 (0.9) |
| #8 | 4824 | 3.58 | 114 (2.4) | 13 (11.4) | 101 (2.1) | 44 (43.6) | 11 (10.9) | 10 (9.9) | 0 |
| #9 | 9436 | 6.67 | 236 (2.5) | 25 (10.6) | 211 (2.2) | 97 (46.0) | 19 (9.0) | 12 (5.7) | 0 |
| #10 | 7104 | 2.75 | 43 (0.6) | 1 (2.3) | 42 (0.6) | 27 (64.3) | 6 (14.3) | 3 (7.1) | 1 (2.4) |
| #11 ¶ | 6522 | 2.97 | 50 (0.8) | 21 (42.0) | 29 (0.4) | 13 (44.8) | 3 (10.3) | 2 (6.9) | 0 |
| Total | 112 462 | 2044 | 446 | 1598 | 733 | 196 | 134 | 16 | |
| Mean % | 3.89 | 1.82 | 21.8 | 1.42 |
% Indicates percentage of total practice population.
*Data obtained from Quality and Outcomes Framework 2013/2014 report.
†Indicates percentage of potentially eligible patients excluded by their general practitioner.
§Indicates percentage of patients invited.
¶Signify general practices which were research-active and had dedicated on-site practice research nurses.
‡Percentage of patients who replied to the STOP-CKD research invitations.
CKD, chronic kidney disease; GP, general practitioner; STOP-CKD, Spironolactone To Prevent Cardiovascular Events in Early Stage CKD.